Zydus & CMS enter pact for Desidustat in Greater China
Posted by
www.biotecnika.org
The agreement is for Desidustat, a novel oral HIF-PH inhibitor for the
treatment of anemia in patients with Chronic Kidney Disease (CKD)
not-on-dialysis and for the treatment of anemia CKD patients on
dialysis in Greater China, Zydus said in a statement. "Under the
license agreement, CMS will pay Zydus an initial upfront payment," it
added.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/zydus-cms-enter-pact-for-desidustat-in-greater-china/articleshow/73434483.cms
Subscribe to:
Post Comments (Atom)
Post a Comment